JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 5, 2007; DOI: 10.1124/jpet.107.129171


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.129171v1
324/1/224    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alier, K. A.
Right arrow Articles by Smith, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alier, K. A.
Right arrow Articles by Smith, P. A.


Received for publication July 25, 2007.
Revised October 2, 2007.
Accepted for publication October 3, 2007.

Intrathecal Administration of Proteinase-Activated Receptor-2 Agonists Produces Hyperalgesia by Exciting the Cell Bodies of Primary Sensory Neurons

Kwai A. Alier 1, Jaclyn A. Endicott 1, Patrick L. Stemkowski 1, Nicolas Cenac 2, Laurie Cellars 2, Kevin Chapman 2, Patricia Andrade-Gordon 3, Nathalie Vergnolle 2, Peter A. Smith 1*

1 University of Alberta 2 University of Calgary 3 Johnson & Johnson, Spring House, PA

* Address correspondence to: E-mail: peter.a.smith{at}ualberta.ca

Abstract

Proteinase-Activated Receptors (PARs) are a family of G-protein-coupled receptors that are activated by endogenous serine proteinases that cleave the N-terminal domain of the receptor unmasking a "tethered ligand" sequence. Trypsin and other agonists at Proteinase Activated Receptor-2 (PAR2) act on peripheral nerves to augment the transfer of nociceptive information. We tested whether PAR2 agonists also exert a spinal pro-nociceptive effect by intrathecally administering the selective ligand, SLIGRL-NH2 (SLIGRL). This produced thermal and mechanical hyperalgesia in rats and mice and augmented mechanical and thermal hyperalgesia seen in the formalin inflammatory pain test. Effects of SLIGRL were abrogated in PAR2-deficient mice and were not seen with the inactive control peptide, LRGILS-NH2 (LRGILS). Surprisingly, electrophysiological studies, using whole-cell recording from rat substantia gelatinosa neurons, failed to demonstrate an increase in excitatory transmission or neuronal excitability following treatment with SLIGRL or trypsin. In fact, the actions of trypsin were consistent with a decrease in dorsal horn excitability. SLIGRL and trypsin did however depolarize and increase the excitability of large, medium and small primary afferent, dorsal root ganglion neurons. The effects were associated with an increase in conductance at hyperpolarized potentials and a decrease in conductance at depolarized potentials. PAR2-like immunoreactivity was found in DRG but not in spinal dorsal horn. These results suggest that activation of DRG neuron cell bodies may account for the pro-nociceptive actions of intrathecally-applied PAR2 agonists. They also imply that pathophysiological release of PAR2-activating proteases in the vicinity of DRG neurons may produce profound effects on nociceptive processing in vivo.


Key words: Dorsal Horn, Dorsal Root Ganglion, PAR2, Primary Afferent, Substantia Gelatinosa, Trypsin





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.